Prediabetes. Abnormal glucose
Conditions
Interventions
Intervention 1: Intervention group: The enrolled patients take one 500 mg herbal quercetin capsule (3,3',4',5,7-pentahydroxyflavone) daily for 12 weeks. Intervention 2: Control group: The enrolled pat
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: People with prediabetes with fasting blood sugar (greater than or equal to 100 and less than 125 mg/dL) or increased blood sugar two hours after prescribing glucose (greater than or equal to 140 and less than 200 mg/dL) or hemoglobin A1C range 5.7% to 6.4% Aged 18 years and older Conscious consent to participate in the study
Exclusion criteria
Exclusion criteria: Pregnancy and lactation consumption of hypoglycemic drugs Consumption of quercetin in the last three months Taking of crocin and curcumin supplementations History of liver and kidney failures and cardiovascular diseases Cancer and autoimmune diseases Dissatisfaction with participating in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting blood sugar level (FBS). Timepoint: Beginning of the study and the end of 12 weeks. Method of measurement: Blood sampling and serum isolation.;Serum insulin level. Timepoint: Beginning of the study and the end of 12 weeks. Method of measurement: Blood sampling and serum isolation.;Level of inflammatory marker CRP. Timepoint: Beginning of the study and the end of 12 weeks. Method of measurement: Blood sampling and serum isolation.;Level of inflammatory marker IL-6. Timepoint: Beginning of the study and the end of 12 weeks. Method of measurement: Blood sampling and serum isolation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Level of HbA1C. Timepoint: Beginning of the study and the end of 12 weeks. Method of measurement: Blood sampling and serum isolation.;Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). Timepoint: Beginning of the study and the end of 12 weeks. Method of measurement: Blood sampling and serum isolation.;Lipid profile levels including LDL, HDL, cholesterol and triglyceride. Timepoint: Beginning of the study and the end of 12 weeks. Method of measurement: Blood sampling and serum isolation.;Levels of liver enzymes ALT and AST. Timepoint: Beginning of the study and the end of 12 weeks. Method of measurement: Blood sampling and serum isolation.;Bilirubin level. Timepoint: Beginning of the study and the end of 12 weeks. Method of measurement: Blood sampling and serum isolation.;Creatinine level. Timepoint: Beginning of the study and the end of 12 weeks. Method of measurement: Blood sampling and serum isolation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMona Kabiri
Mashhad University of Medical Sciences
Outcome results
None listed